Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib versus imatinib with reduced-intensity chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
2023-508463-71-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing Ponatinib + reduced-intensity chemotherapy with Imatinib + reduced-intensity chemotherapy (2 arms). Primary endpoint: MRD-negative complete remission. Planned start Nov 2018; status: authorised.
02
Drugs
ponatinibimatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2023-508463-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508463-71-00.